Vaidya Sane Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 4- Conservative revenue guidance for FY25: around Rs. 97 to 100 crores, similar to last year’s turnover.
- EBITDA margins expected to sustain or improve due to cost efficiencies (HR cost reduction, professional fees optimization, and controlled COGS).
- Expansion plans for hospitals include adding 40-60 beds each at Khopoli and Kondhali hospitals within 12-18 months.
- Long-term vision to add 10 more hospitals, focusing on acquisitions and franchise-like expansions, especially in North India, Gujarat, and South India.
- Plans to establish about 1,000 clinics, 10 hospitals, and 5,000 outpatient departments by 2030, targeting rural areas.
- FMCG (Madhavprash) expected to grow gradually with marketing ramp-up and increased retail inquiries.
- Marketing efforts are being optimized, with a strong focus on treatment-first approach to drive patient volume growth.
- Potential patient surge anticipated with Ayushman Bharat's Ayurvedic coverage, supported by expanding infrastructure and NABH accreditation.
See what Vaidya Sane management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any new fundraising through debt in the call transcript.
- Dr. Rohit Madhav Sane mentioned preferential share allotment subscription for himself expected to finalize within a month, with a dilution of less than 5%.
- The preferential allotment funds might be used for capex related to hospital bed additions, especially at Khopoli hospital.
- No other specific equity or debt fundraising plans were disclosed for current or future periods.
- The company appears to focus on internal accruals and conservative revenue guidance for growth and CAPEX.
See what Vaidya Sane management said on order book — free account, 30 seconds.
Capex plans
Yes- Khopoli hospital: Plans to add 80 more beds on adjacent land over 12-18 months, in phases of 20-40 beds; estimated cost Rs. 8-10 crores. Awaiting government permissions (~1 month).
- Nagpur hospital: Planning an addition of 20 beds in next 12-18 months.
- Expansion focus on acquiring existing hospitals or resorts and converting them into Madhavbaug facilities through a franchise-like model, targeting North India, Gujarat, and South India.
- Future plan includes adding 40 to 60 beds in Khopoli and Kondhali hospitals within the next 12-18 months.
- Expansion being funded through preferential allotment and internal accruals.
- No immediate new hospital openings planned for 6-8 months; focus on consolidating existing hospital capacity and marketing.
- Long-term vision: Add 10 hospitals and about 1,000 clinics by 2030 with emphasis on rural areas.
Track Vaidya Sane — get its next earnings analysis in your feed
Margin guidance
Category 1- The company expects a conservative revenue of around Rs. 97-100 crores for the full year FY25, similar to last year’s turnover.
- EBITDA margins are expected to sustain and potentially improve beyond current levels due to optimized HR costs, reduced COGS (22-24%), and controlled professional fees.
- PAT is projected to rise significantly, with a potential increase from Rs. 2.3 crores (last year) to Rs. 7-8 crores for the full year.
- EBITDA margin improvement is anticipated as topline grows since fixed costs like HR and professional fees won't increase proportionally.
- A 700% profit jump is forecasted for the full year compared to the previous year.
- Expansion plans include adding 40-60 beds in existing hospitals within 12-18 months, aiming for growth primarily in hospital business due to higher margins.
- FMCG business growth is gradual, focusing on increasing sales of products like Madhavprash, with marketing plans to scale up sales in the near term.
Order book
How does Vaidya Sane rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does Vaidya Sane rank in Healthcare Equipment & Supplies?
Compare Vaidya Sane against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Vaidya Sane's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
- Tarsons Products (Q2 FY26)
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
- Tarsons Products (Q3 FY26)
Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026. Key concall takeaways from Tarsons…